These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

976 related articles for article (PubMed ID: 32998997)

  • 61. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
    Watson M; Roulston A; Bélec L; Billot X; Marcellus R; Bédard D; Bernier C; Branchaud S; Chan H; Dairi K; Gilbert K; Goulet D; Gratton MO; Isakau H; Jang A; Khadir A; Koch E; Lavoie M; Lawless M; Nguyen M; Paquette D; Turcotte E; Berger A; Mitchell M; Shore GC; Beauparlant P
    Mol Cell Biol; 2009 Nov; 29(21):5872-88. PubMed ID: 19703994
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
    Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
    Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
    [TBL] [Abstract][Full Text] [Related]  

  • 63. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.
    Pittelli M; Cavone L; Lapucci A; Oteri C; Felici R; Niccolai E; Amedei A; Chiarugi A
    Immunol Cell Biol; 2014 Feb; 92(2):191-9. PubMed ID: 24275857
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma.
    Lailler C; Louandre C; Morisse MC; Lhossein T; Godin C; Lottin M; Constans JM; Chauffert B; Galmiche A; Saidak Z
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31467175
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rapid tumor recurrence in a novel murine GBM surgical model is associated with Akt/PD-L1/vimentin signaling.
    Liu F; Xu XH; Li CY; Zhang TT; Yin SL; Liu GQ; Hu F; Yu SB; Chen XQ
    Biochem Biophys Res Commun; 2021 Sep; 569():1-9. PubMed ID: 34216991
    [TBL] [Abstract][Full Text] [Related]  

  • 67. NAD
    Moore AM; Zhou L; Cui J; Li L; Wu N; Yu A; Poddar S; Liang K; Abt ER; Kim S; Ghukasyan R; Khachatourian N; Pagano K; Elliott I; Dann AM; Riahi R; Le T; Dawson DW; Radu CG; Donahue TR
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33597293
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.
    Inocencio JF; Mitrasinovic S; Asad M; Parney IF; Zang X; Himes BT
    Front Immunol; 2024; 15():1424396. PubMed ID: 39346924
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
    Saha D; Martuza RL; Rabkin SD
    Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 73. NAMPT pathway is involved in the FOXO3a-mediated regulation of GADD45A expression.
    Thakur BK; Lippka Y; Dittrich T; Chandra P; Skokowa J; Welte K
    Biochem Biophys Res Commun; 2012 Apr; 420(4):714-20. PubMed ID: 22430142
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
    Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
    Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
    [TBL] [Abstract][Full Text] [Related]  

  • 75. NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma.
    Guo Q; Han N; Shi L; Yang L; Zhang X; Zhou Y; Yu S; Zhang M
    Oncol Rep; 2019 Sep; 42(3):963-972. PubMed ID: 31322259
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.
    Bruzzone S; Fruscione F; Morando S; Ferrando T; Poggi A; Garuti A; D'Urso A; Selmo M; Benvenuto F; Cea M; Zoppoli G; Moran E; Soncini D; Ballestrero A; Sordat B; Patrone F; Mostoslavsky R; Uccelli A; Nencioni A
    PLoS One; 2009 Nov; 4(11):e7897. PubMed ID: 19936064
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model.
    Clausing M; William D; Preussler M; Biedermann J; Grützmann K; Richter S; Buchholz F; Temme A; Schröck E; Klink B
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628596
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages.
    Zhu Z; Zhang H; Chen B; Liu X; Zhang S; Zong Z; Gao M
    Front Immunol; 2020; 11():588552. PubMed ID: 33329573
    [TBL] [Abstract][Full Text] [Related]  

  • 79. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
    Vachher M; Arora K; Burman A; Kumar B
    J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth.
    Yan Z; Huang L; Zhang X; Yu X; Huang R
    Sci Rep; 2024 Aug; 14(1):18444. PubMed ID: 39117725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.